![]() Harms may exceed benefits for persons starting aspirin in their 70s and for many during the first 10 to 20 years of use. ![]() Results of Base-Case Analysis: Lifetime net quality-adjusted life-years are positive for most adults initiating aspirin at ages 40 to 69 years, and life expectancy gains are expected for most men and women initiating aspirin at ages 40 to 59 years and 60 to 69 years with higher CVD risk. Harms include increased fatal and nonfatal GI bleeding and hemorrhagic stroke. Benefits include reduced nonfatal myocardial infarction, nonfatal ischemic stroke, fatal CVD, CRC incidence, and CRC mortality. Outcome Measures: Primary outcomes are length and quality of life measured in net life-years and quality-adjusted life-years. Intervention: Low-dose aspirin (≤100 mg/d). Time Horizon: Lifetime, 20 years, and 10 years. Target Population: Men and women aged 40 to 79 years with a 10-year CVD risk of 20% or less, and no history of CVD and without elevated risk for GI or cerebral hemorrhages that would contraindicate aspirin use. Objective: To assess the net balance of benefits and harms from routine aspirin use across clinically relevant age, sex, and CVD risk groups.ĭesign: Decision analysis using a microsimulation model.ĭata Sources: 3 systematic evidence reviews. ![]() Background: Evidence indicates that aspirin is effective for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) but also increases the risk for gastrointestinal (GI) and cerebral hemorrhages.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |